Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy

Océane Landon-Cardinal1,2,3, Yves Allenbach4,5,6, Antoine Soulages4,5,6

  • 1From the Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, AP-HP, East Paris Neuromuscular Diseases Reference Center, Inserm U974, Sorbonne Université, Paris, France; Center of Reference for Neuromuscular Disorders AOC, Department of Neurology, Bordeaux University Hospital, Bordeaux, France; Polyvalent and Oncologic Radiology Department, Musculoskeletal Unit, Pitié-Salpêtrière University Hospital, AP-HP, Paris, France. o.landoncardinal@gmail.com.

The Journal of Rheumatology
|December 17, 2018
PubMed
Abstract